Physician profile
Michael L Thomas
NPI 1700847589
$22,367.21
in general payments reported to CMS, 2019-2025
28 companies · $12K in 2025
The $12K reported for 2025 was more than what 95% of Surgery providers received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,073 · 2020: $462 · 2021: $278 · 2022: $3,763 · 2023: $1,252 · 2024: $2,790 · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $10K · Travel and Lodging: $3,725 · Food and Beverage: $1,663 · Gift: $8.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $10,395.00 |
| Travel and Lodging | $3,724.64 |
| Food and Beverage | $1,662.98 |
| Gift | $8.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $12,397.46 | 2019-2025 | Spy-Phi System, 1788, Inspyre |
| Intuitive Surgical, INC. | $5,164.75 | 2020-2024 | Da Vinci Surgical System |
| Tela Bio, INC. | $1,849.66 | 2019-2024 | Ovitex 2s |
| Atricure, INC. | $950.30 | 2019 | |
| Boston Scientific Corporation | $363.77 | 2020-2025 | Spyglass Discover |
| Medtronic, INC. | $206.20 | 2021-2025 | Transorb, Ligasure, Progrip |
| Allergan, INC. | $182.94 | 2020-2022 | |
| Applied Medical Resources Corporation | $160.74 | 2025 | Gelport Laparoscopic System |
| Kci USA, INC. | $137.60 | 2019 | |
| Davol INC. | $135.43 | 2020-2021 | |
| Baxter Healthcare | $107.58 | 2024 | Perclot |
| Genentech USA, INC. | $103.74 | 2019 | |
| Novartis Pharmaceuticals Corporation | $95.92 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $75.17 | 2019-2020 | |
| Polynovo North America LLC | $71.86 | 2025 | Novosorb Btm |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $56.18 | 2019-2020 | |
| Organogenesis INC. | $43.27 | 2024-2025 | Via Matrix |
| Janssen Biotech, INC. | $32.99 | 2019-2020 | |
| Seagen INC. | $31.64 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $27.41 | 2019 | |
| Covidien LP | $27.09 | 2019-2020 | |
| Ipsen Biopharmaceuticals, INC | $26.63 | 2020 | |
| Pharmacosmos Therapeutics INC. | $26.55 | 2023 | Monoferric |
| Abbvie INC. | $24.88 | 2024 | |
| Innocoll Pharmaceuticals Limited | $21.13 | 2021 | |
| Genzyme Corporation | $17.03 | 2019 | |
| Celgene Corporation | $15.12 | 2019 | |
| Pfizer INC. | $14.17 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.